Kano Therapeutics Secures $7.1M to Bring Targeted, Non-Viral DNA Insertion Technology to Genetic Medicine
Spun out of MIT, the company is engineering a new class of biomolecules at 10x lower cost and drastically increased scale to advance gene editing toward cures for complex diseases. August 12, 2024 05:00 AM…